{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T14:04:21Z","timestamp":1790949861167,"version":"4.1.0"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To report on the efficacy and safety of elective switching from intravenously (IV) to subcutaneously (SC) administered Infliximab (IFX) in patients with immune mediated diseases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective analysis of patients with Crohn\u2019s disease (CD), Ulcerative Colitis (UC), Spondyloarthritis (SpA), Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) and chronic plaque Psoriasis (PsO) who were receiving IFX-IV for maintenance of remission in tertiary referral centers and were switched to IFX-SC based on their physician\u2019s choice. All patients with gastrointestinal and skin diseases were in clinical remission, while those with musculoskeletal disease had inactive disease or low disease activity. The primary endpoint was disease deterioration during a follow up period, of at least 6\u202fmonths, according to disease specific composite measures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Between April 2023 and April 2024, a total of 344 patients (CD\u202f=\u202f136, UC\u202f=\u202f62, SpA\u202f=\u202f52, PsA\u202f=\u202f38, RA\u202f=\u202f7, PsO\u202f=\u202f44, co-existence of more than one disease\u202f=\u202f5) were switched from IFX-IV to IFX-SC. After a mean\u00b1SD follow up period of 8\u202f\u00b1\u202f4\u202fmonths, 12 patients (3.5%) discontinued treatment with IFX-SC. Five of them (1.5%) because of disease worsening and the remaining 7 (2.0%) because of the occurrence of side effects. All 332 other patients (96.5%) showed favorable response, none of them requested an unscheduled visit, or developed an adverse event (clinical or laboratory) or needed escalation of treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Elective switching from IFX-IV to IFX-SC seems to be an effective and safe approach in real-world every day clinical practice to maintain long-term clinical remission, inactive disease or low disease activity in patients with immune-mediated diseases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2025.1583401","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T09:21:37Z","timestamp":1747387297000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Switching from intravenous to subcutaneous infliximab in patients with immune mediated diseases in clinical remission"],"prefix":"10.3389","volume":"12","author":[{"given":"Nikos","family":"Viazis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasios","family":"Karamanakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Mousourakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angeliki","family":"Christidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fotios","family":"Fousekis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Mpakogiannis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasios","family":"Koukoudis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Katsanos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Christodoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myrto","family":"Cheila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Tzouvala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eirini","family":"Zacharopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Palatianou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Giouleme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Katsoula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Liatsos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Kyriakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evi","family":"Zampeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgenia","family":"Papathanasiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angeliki","family":"Theodoropoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Karmiris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Psaroudakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Tribonias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souzanna","family":"Gazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelia","family":"Mole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodoros","family":"Dimitroulas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Koutsianas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitris","family":"Vassilopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George E.","family":"Fragoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikos","family":"Michalakeas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charalampos","family":"Papagoras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pantelis","family":"Panagakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Papoutsaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki","family":"Chasapi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandros","family":"Stratigos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Katsikas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,16]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1136\/pgmj.2006.052688","article-title":"Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution","volume":"83","author":"Kuek","year":"2007","journal-title":"Postgrad Med J"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.crohns.2013.03.011","article-title":"ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD)","volume":"7","author":"Danese","year":"2013","journal-title":"J Crohns Colitis"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/nrrheum.2015.110","article-title":"Biosimilars in rheumatology: current perspectives and lessons learnt","volume":"11","author":"Dorner","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s40261-021-01093-8","article-title":"Subcutaneous infliximab, CT-P13 SC: a profile of its use in the EU","volume":"41","author":"Shirley","year":"2021","journal-title":"Clin Drug Investig"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1093\/rheumatology\/keaa580","article-title":"Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I\/III trial","volume":"60","author":"Westhovens","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1053\/j.gastro.2021.02.068","article-title":"Randomized controlled trial: subcutaneous vs intravenous infliximab CT-P13 maintenance in inflammatory bowel disease","volume":"160","author":"Schreiber","year":"2021","journal-title":"Gastroenterology"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: medical treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J Crohn's Colitis"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","article-title":"ECCO guidelines on therapeutics in Crohn's disease: medical treatment","volume":"14","author":"Torres","year":"2020","journal-title":"J Crohn's Colitis"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1007\/s11926-024-01134-z","article-title":"Year in review in axial Spondyloarthritis clinical research and guidelines: SPARTAN 2023 annual meeting proceedings","volume":"26","author":"Dubreuil","year":"2024","journal-title":"Curr Rheumatol Rep"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1136\/ard-2024-225531","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update","volume":"83","author":"Gossec","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1001\/jamadermatol.2019.4029","article-title":"Comparison of biologics and Oral treatments for plaque psoriasis: a meta-analysis","volume":"156","author":"Armstrong","year":"2020","journal-title":"JAMA Dermatol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1111\/j.1365-2036.2010.04234.x","article-title":"Systematic review: the costs of ulcerative colitis in Western countries","volume":"31","author":"Cohen","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1002\/ibd.22873","article-title":"Comparison of medical costs among patients using adalimumab and infliximab: a retrospective study (COMPAIRS)","volume":"18","author":"Sussman","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1053\/j.gastro.2020.04.012","article-title":"AGA clinical practice update on management of inflammatory bowel disease during the COVID-19 pandemic: expert commentary","volume":"159","author":"Rubin","year":"2020","journal-title":"Gastroenterology"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.1097\/MIB.0000000000000967","article-title":"Costs of Crohn\u2019s disease according to severity states in France: a prospective observational study and statistical modelling over 10 years","volume":"22","author":"Boschetti","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"549","DOI":"10.20524\/aog.2023.0816","article-title":"Safety and efficacy of transitioning inflammatory bowel disease patients from intravenous to subcutaneous infliximab: a single-center real-world experience","volume":"36","author":"Jeffrey","year":"2023","journal-title":"Ann Gastroenterol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1111\/apt.17822","article-title":"Long-term effectiveness and acceptability of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel disease treated with intensified doses: the REMSWITCH-LT study","volume":"59","author":"Buisson","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1093\/ecco-jcc\/jjac053","article-title":"Efficacy and safety of elective switching from intravenous to subcutaneous infliximab [CT-P13]: a multicentre cohort study","volume":"16","author":"Smith","year":"2022","journal-title":"J Crohns Colitis"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"e14283","DOI":"10.1111\/eci.14283","article-title":"An international multicentre study of switching from intravenous to subcutaneous infliximab and vedolizumab in inflammatory bowel diseases: the TIME study","volume":"54","author":"D\u2019Amico","year":"2024","journal-title":"Eur J Clin Investig"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/j.dld.2023.12.013","article-title":"Switching from intravenous to subcutaneous infliximab maintenance therapy in inflammatory bowel disease: post hoc longitudinal analysis of a randomized trial","volume":"56","author":"Schreiber","year":"2024","journal-title":"Dig Liver Dis"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"667","DOI":"10.5009\/gnl230291","article-title":"Effectiveness of switching to subcutaneous infliximab in ulcerative colitis patients experiencing intravenous infliximab failure","volume":"18","author":"Bae","year":"2024","journal-title":"Gut Liver"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1093\/rheumatology\/keac689","article-title":"Efficacy of subcutaneous vs intravenous infliximab in rheumatoid arthritis: a post-hoc analysis of a randomized phase III trial","volume":"62","author":"Constantin","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"e05205","DOI":"10.1002\/ccr3.5205","article-title":"Real-world evidence for subcutaneous infliximab (CT-P13 SC) treatment in patients with psoriatic arthritis during the coronavirus disease (COVID-19) pandemic: a case series","volume":"10","author":"Baraliakos","year":"2022","journal-title":"Clin Case Rep"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1583401\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T09:21:37Z","timestamp":1747387297000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1583401\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,16]]},"references-count":24,"alternative-id":["10.3389\/fmed.2025.1583401"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1583401","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,16]]},"article-number":"1583401"}}